Kim Yeu-Chun, Ludovice Peter J, Prausnitz Mark R
Center for Drug Design, Development and Delivery and the Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, United States.
J Control Release. 2007 Oct 8;122(3):375-83. doi: 10.1016/j.jconrel.2007.05.031. Epub 2007 Jun 2.
In this study we tested the hypothesis that magainin, a peptide known to form pores in bacterial cell membranes, can increase skin permeability by disrupting stratum corneum lipid structure. We further hypothesized that magainin's enhancement requires co-administration with a surfactant chemical enhancer to increase magainin penetration into the skin. In support of these hypotheses, exposure to a known surfactant chemical enhancer, N-lauroyl sarcosine (NLS), in 50% ethanol solution increased in vitro skin permeability to fluorescein 15 fold and the combination of magainin and NLS-ethanol synergistically increased skin permeability 47 fold. In contrast, skin permeability was unaffected by exposure to magainin without co-enhancement by NLS-ethanol. Furthermore, confocal microscopy showed that magainin in the presence of NLS-ethanol penetrated deeply and extensively into stratum corneum, whereas magainin alone penetrated poorly into the skin. Additional analysis by Fourier-transform infrared spectroscopy, X-ray diffraction, and differential scanning calorimetry showed that NLS-ethanol disrupted stratum corneum lipid structure and that the combination of magainin and NLS-ethanol disrupted stratum corneum lipids even further. Altogether, these data suggest that NLS-ethanol increased magainin penetration into stratum corneum, which further increased stratum corneum lipid disruption and skin permeability. We believe this is the first study to demonstrate the use of a pore-forming peptide to increase skin permeability. This study also presents the novel concept of using a first chemical enhancer to increase penetration of a second chemical enhancer into the skin to synergistically increase skin permeability to a model drug.
在本研究中,我们验证了以下假设:蛙皮抗菌肽(一种已知可在细菌细胞膜上形成孔道的肽)能够通过破坏角质层脂质结构来增加皮肤通透性。我们进一步假设,蛙皮抗菌肽发挥增强作用需要与一种表面活性剂化学增强剂共同给药,以增加蛙皮抗菌肽渗透进入皮肤的能力。为支持这些假设,在50%乙醇溶液中加入已知的表面活性剂化学增强剂N-月桂酰肌氨酸(NLS),可使体外皮肤对荧光素的通透性提高15倍,而蛙皮抗菌肽与NLS-乙醇联合使用可使皮肤通透性协同提高47倍。相比之下,在没有NLS-乙醇共同增强作用的情况下,接触蛙皮抗菌肽并不会影响皮肤通透性。此外,共聚焦显微镜显示,在NLS-乙醇存在的情况下,蛙皮抗菌肽能深入且广泛地渗透进入角质层,而单独的蛙皮抗菌肽对皮肤的渗透较差。通过傅里叶变换红外光谱、X射线衍射和差示扫描量热法进行的进一步分析表明,NLS-乙醇破坏了角质层脂质结构,而蛙皮抗菌肽与NLS-乙醇的组合对角质层脂质的破坏作用甚至更大。总之,这些数据表明,NLS-乙醇增加了蛙皮抗菌肽对角质层的渗透,进而进一步增加了角质层脂质破坏和皮肤通透性。我们认为这是第一项证明使用成孔肽来增加皮肤通透性的研究。本研究还提出了一个新颖的概念,即使用第一种化学增强剂来增加第二种化学增强剂渗透进入皮肤的能力,从而协同增加皮肤对模型药物的通透性。